PT  - JOURNAL ARTICLE
AU  - Joint Head and Neck Radiotherapy-MRI Development Cooperative
AU  - the MD Anderson Head and Neck Cancer Symptom Working Group
AU  - Keith L. Sanders
AU  - Sam Mulder
AU  - Kareem A. Wahid
AU  - Brigid A. McDonald
AU  - Sara Ahmed
AU  - Travis C. Salzillo
AU  - Renjie He
AU  - Mohamed A. Naser
AU  - Cem Dede
AU  - Vivian Salama
AU  - Ashley Way
AU  - Christina Setareh Sharafi
AU  - Abdallah S.R. Mohamed
AU  - Jillian Rigert
AU  - Mark Chambers
AU  - Amy C. Moreno
AU  - Katherine A. Hutcheson
AU  - Stephen Y. Lai
AU  - Clifton D. Fuller
AU  - Lisanne V. van Dijk
TI  - Improved Xerostomia Prediction in Head and Neck Cancer Patients with Dixon Magnetic Resonance Imaging of Glandular Adiposity: Validation of Semi-Quantitative Parotid T1 Signal Intensity Metrics for Biomarker Pre-Qualification
AID  - 10.1101/2022.07.11.22277439
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.07.11.22277439
4099  - http://medrxiv.org/content/early/2022/07/12/2022.07.11.22277439.short
4100  - http://medrxiv.org/content/early/2022/07/12/2022.07.11.22277439.full
AB  - Purpose Parotid whole-gland magnetic resonance (MR) T1 intensity, thresholded at the 90th percentile (T1 P90), has been previously reported to be a candidate MR imaging biomarker (MR-IBM) for improved prediction of xerostomia development after radiotherapy. Although P90 was previously derived from the parotid glands of T1-weighted MRI, in this study, we aim to validate P90 in an external cohort using fat only images reconstructed from a T1 Dixon MRI sequence, as well as determining alternative T1 intensity thresholds for potential qualification as predictive FDA BEST biomarkers of xerostomia development 6 months after radiotherapy (Xero6m).Methods MR-IBMs derived from T1 Dixon intensity-normalized scans from 76 head and neck cancer (HNC) patients were extracted from pre-treatment MR images. Scans were normalized to fat tissue, and imaging characteristics were quantified. A reference model and MR-IBM models were created using multivariable logistic regression to predict Xero6m. External validation was performed using the model coefficients described in a previous study. The area under the curve (AUC) of the resulting models were compared. Stepwise forward feature selection was performed to discover additional MR-IBMs for improved predictions of xerostomia.Results The external validation of a previous model coefficients against our cohort showed decreased performance of the P90 MR-IBM model (AUC of 0.73 (CI 0.61-0.85)). The reference model exhibited improved performance when P90 was incorporated (AUC of 0.78 (CI 0.67-0.89)). Feature selection demonstrated the P10 MR-IBM provided performance improvements (AUC of 0.79 (CI: 0.69-0.90)).Conclusion Our findings validated P90 as predictive biomarker for radiation-induced xerostomia and showed MR-IBMs derived from Dixon sequences can improve Xero6m prediction when compared to the reference model. Formal biomarker qualification should be considered for T1 sequences/relaxometry via formalized approaches.Competing Interest StatementCDF has received direct industry grant support, honoraria, and travel funding from Elekta AB unrelated to this project. Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT03145077 Funding StatementFunding/acknowledgements: KLS was supported by the National Institutes of Health (NIH) National Institute for Craniofacial and Dental Research (NIDCR) Research Supplement to Promote Diversity in Health-Related Research (DE028290-01S1). SM is supported by direct funds from the NIDCR (R01 DE028290). KAW received/receives support from the Dr. John J. Kopchick Fellowship through The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, the American Legion Auxiliary Fellowship in Cancer Research, The University of Texas Health Science Center at Houston (UTHealth) Center for Clinical and Translational Sciences (CCTS) TL1 Program (TL1TR003169), and an NIH NIDCR Graduate Fellowship (F31DE031502). BAM received/receives support via the Dr. John J. Kopchick Fellowship, and an NIH NIDCR Graduate Fellowship (F31DE029093). TCS received/receives funding support from the UTHealth CCTS TL1 Program (TL1TR003169). CD received/receives funding support from the NIH/National Science Foundation (NSF) National Cancer Institute (NCI) Smart and Connected Health Program (R01CA257814-01). ASRM received/receives funding and salary support from related to this project from: NIDCR Academic Industrial Partnership Grant (R01DE028290); NIDCR Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions award (R01DE025248); NIH/NSF NCI Smart Connected Health Program (R01CA257814). AW received direct support from the NCI Small Business Innovation Research Grant Program through a Research Supplement to Promote Diversity (R43CA254559-S1). JR receives direct support from a NIDCR Research Supplement to Promote Diversity in Health-Related Research (DE028290-S2). ACM received/receives support from the NCI Paul Calabresi Clinical Trial Program (K12CA088084), a NIDCR NIH Exploratory/Developmental Research Grant Program (R21DE031082), and a NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Workforce (K01 DE030524). KAH received/receives support from the Patient-Centered Outcomes Research Institute (PCORI) (PCS-1609-36195) and NCI Clinical and Translational Exploratory/Developmental Studies Grant (R21CA226200). SYL received/receives support from an NCI Exploratory/Developmental Bioengineering Research Grant (R21CA259839), NIDCR Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions Grant (R01DE025248), and the Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant Program (T32CA261856). CDF received/receives funding and salary support during the period of study execution from: the NIH National Institute of Biomedical Imaging and Bioengineering (NIBIB) Research Education Programs for Residents and Clinical Fellows Grant (R25EB025787); NIDCR Academic Industrial Partnership Grant (R01DE028290); NCI Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program (1R01CA218148); NCI Institutional Research Training Grant Program (T32CA261856); NIDCR NIH Exploratory/Developmental Research Grant Program (R21DE031082); the NCI SBIR Grant Program (R43CA254559); an NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from the UT MD Anderson CCSG Radiation Oncology and Cancer Imaging Program Seed Grant (P30CA016672); a Joint NSF/NIH Initiative on Quantitative Approaches to Biomedical Big Data (QuBBD) Grant (R01CA225190); and an NSF Division of Civil, Mechanical, and Manufacturing Innovation (CMMI) grant (NSF 1933369). CDF has received direct industry grant support, honoraria, and travel funding from Elekta AB unrelated to this project. LvD was supported by a grant from the Dutch Research Council/Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO 452182317) and with a Young Investigator Grant from KWF Dutch Cancer Society (KWF 13529. Direct infrastructure support is provided to by the multidisciplinary the Radiation Oncology/Cancer Imaging Program (P30CA016672-44) of the MD Anderson Cancer Center Support Grant (P30CA016672), the MD Anderson Cancer Center Stiefel Oropharyngeal Research Fund, and the MD Anderson Program in Image-guided Cancer Therapy. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of MD Anderson Cancer Center gave ethical approval for this secondary data analysis with waiver of informed consent (RCR03-0800); patients had previously supplied consent to the primary protocol under which data was collected, PA16-0302(NCT03145077).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAssociated data are available as an online repository at figshare.com, pending completion of peer review. https://doi.org/10.6084/m9.figshare.20278068